Hepatitis C infection in Iran; A review article

Iranian Journal of Clinical Infectious Diseases

Volumn 4, Issue 1, 2009, Pages 47-59

  Alavian, Seyed Moayed ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIBODY; VIRUS RNA;

BLOOD DONOR; BLOOD TRANSFUSION; HEMODIALYSIS; HEMOPHILIA A; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HOSPITAL INFECTION; HUMAN; INCIDENCE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; IRAN; PREVALENCE; REVIEW; RISK FACTOR; RISK REDUCTION; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; TATTOOING; THALASSEMIA; UREMIA; VIRUS TRANSMISSION;

EID: 77953466924     PISSN: 17355109     EISSN: 20081081     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Brown RS Jr, Gaglio PJ. Scope of worldwide hepatitis C problem. Liver Transpl 2003;9(11):S10-3.
2. Alavian SM. We need a new national approach to control hepatitis C: It is becoming too late. Hepatitis Monthly 2008;8(3):1-3.
3. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iranian Med 2005;8:84-90.
4. Alavian SM, Fallahian F, Bagheri-Lankarani K. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis 2007;16(4):403-6.
5. Gish RG, Lau JYN. Hepatitis C virus: eight years old. Viral Hepatitis Rev 1997;3:17.
6. Bielawski K, Wlasiuk M, Truskolawska M, Falkiewicz B. HCV infection in Poland. Arch Med Res 2000;31(5):532-5.
7. De Carli G, Puro V, Ippolito G. Risk of hepatitis C virus transmission following percutaneous exposure in healthcare workers. Infection 2003;31 Suppl 2:22-7.
8. Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002;155(7):645-53.
9. Zhou F, Ma ZE, Hu W, Feng ZL, Chen KL, Qin GM, et al. Study on the relationship between hepatitis C virus infection and sharing injection equipment, sexual behavior among injecting drug users. Zhonghua Liu Xing Bing Xue Za Zhi 2004;25(4):329-32.
10. Vidal-Trecan GM, Varescon-Pousson I, Gagniere B, Tcherny-Lessenot S, Madariaga E, Boissonnas A. Association between first injection risk behaviors and hepatitis C seropositivity among injecting drug users. Ann Med Interne (Paris) 2002;153(4):219-25.
11. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007;18(5):352-8.
12. Hwang SJ, Lee SD, Lu RH, Chu CW, Wu JC, Lai ST, et al. Hepatitis C viral genotype influences the clinical outcome of patients with acute posttransfusion hepatitis C. J Med Virol 2001;65(3):505-9.
13. Donahue JG, Munoz A, Ness PM, Brown DE, Jr., Yawn DH, McAllister HA, Jr., et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992;327(6):369-73.
14. Ambrozaitis A, KS ZA, Balc Iunaite G, Widell A. Hepatitis C in Lithuania: incidence, prevalence, risk factors and viral genotypes. Clin Diagn Virol 1995;4(4):273-84.
15. Alavian SM, Gholami B, Masarrat S. Hepatitis C risk factors in Iranian volunteer blood donors: A case-control study. J Gastroenterol Hepatol 2002;17(10): 1092-7.
16. Alavian SM, Fallahian F. Comparison of seroepidemiology and transmission modes of viral hepatitis C in Iran and Pakistan. Hepatitis Monthly 2008;8(1):51-9.
17. Stark K, Bienzle U, Vonk R, Guggenmoos-Holzmann I. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. Int J Epidemiol 1997;26(6):1359-66.
18. Alavian SM, Fallahian F, Pakistan CoSaTMoVHCiIa. Comparison of seroepidemiology and transmission modes of viral hepatitis C in Iran and Pakistan. Hepatitis Monthly 2008;8(1):51-9.
19. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996;86(5):655-61.
20. Jabbari A, Besharat S, Khodabakhshi B. Hepatitis C in hemodialysis centers of Golestan province, northeast of Iran (2005). Hepatitis Monthly 2008;8(1):61-5.
21. Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int 1998;53(4): 1022-5.
22. Alavian SM. A shield against a moster: Hepatitis C in hemodialysis patients. World J Gastroenterol 2009;15(6):641-6.
23. Win N, Frame D, Watkins R, Mitchell R. The low risk of hepatitis C virus transmission among sexual partners of confirmed HCV-positive blood donors. Transfus Med 1994;4(3):243-4.
24. Marcellin P, Colin JF, Martinot-Peignoux M, Pham BN, Lefort V, Picault AB, et al. Hepatitis C virus infection in anti-HIV positive and negative French homosexual men with chronic hepatitis: comparison of second- and third-generation anti-HCV testing. Liver 1993;13(6):319-22.
25. Thomas SL, Newell ML, Peckham CS, Ades AE, Hall AJ. A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. Int J Epidemiol 1998;27(1):108-17.
26. Mohtasham Amiri Z, Rezvani M, Jafari Shakib R, Jafari Shakib A. Prevalence of hepatitis C virus infection and risk factors of drug using prisoners in Guilan province. East Mediterr Health J 2007;13(2):250-6.
27. Mohammad-Alizadeh AH, Alavian SM, Jafari K, Yazdi N. Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan--Iran. World J Gastroenterol. 2005;11(26): 4085-9.
28. Hosseini Asl SK, Avijgan M, Mohamadnejad M. High prevalence of HBV, HCV, and HIV infections in Gypsy population residing in Shahr-E-Kord. Arch Iranian Med. 2004;7(1):20-2.
29. Hajiani E, Hashemi J, Masjedizadeh R, Shayesteh AA, Idani E, Rajabi T. Seroepidemiology of hepatitis C and its risk factors in Khuzestan Province, south-west of Iran: a case-control study. World J Gastroenterol 2006;12(30):4884-7.
30. Hajiani E, Masjedizadeh R, Hashemi J, Azmi M, Rajabi T. Hepatis C virus transmission and its risk factors within families of patients infected with hepatitis C virus in southern Iran: Khuzestan. World J Gastroenterol 2006;12(43):7025-8.
31. Sultan F, Mehmood T, Mahmood MT. Infectious pathogens in volunteer and replacement blood donors in Pakistan: a ten-year experience. Int J Infect Dis 2007;11(5):407-12.
32. Mujeeb SA. Unsafe injections: a potential source of HCV spread in Pakistan. J Pak Med Assoc 2001;51(1):1-3.
33. Mujeeb SA, Khatri Y, Khanani R. Frequency of parenteral exposure and seroprevalence of HBV, HCV, and HIV among operation room personnel. J Hosp Infect 1998;38:133-7.
34. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ 1999;77(10):789-800.
35. Agboatwalla M, Isomura S, Miyake K, Yamashita T, Morishita T, Samin Akram D. Hepatitis A, B and C seroprevalence in Pakistan. Indian J Pediatr 1994;61:545-9.
36. Shah HA, Jafri W, Malik I, Prescott L, Simmonds P. Hepatitis C virus (HCV) genotypes and chronic liver disease in Pakistan. J Gastroenterol Hepatol 1997;12(11):758-61.
37. Zuberi SJ, Arif A. Serotyping of the hepatitis C in Pakistan. J Pak Med Assoc 2002;52(5):218-9.
38. Hoofnagle JH, Ghany MG, Kleiner DE, Doo E, Heller T, Promrat K, et al. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology 2003;38(1):66-74.
39. Bari A, Akhtar S, Rahbar MH, Luby SP. Risk factors for hepatitis C virus infection in male adults in Rawalpindi-Islamabad, Pakistan. Trop Med Int Health 2001;6(9):732-8.
40. Motlagh ME, Makvandi M, Jalali MT. Prevalence of anti-HCV among pregnant women. Journal of Qazvin University of Medical Sciences 2001(18):59-63. (Abstract)
41. Vahdani P, Hosseini-Moghaddam SMM, Gachkar L, Sharafi K. Prevalence of hepatitis B, hepatitis C, human immunodeficiency virus, and syphilis among street children residing in southern Tehran, Iran. Arch Iranian Med 2006;9(2):153-55.
42. Mansoor-Ghana'i F, Fallah MS, Ja'farshad R, Joukar F, Poortahmasbi A, Bahari-Moghaddam A. Seroprevalence of hepatitis B and C among residents of Guilan Nursing Home. Hepatitis Monthly 2007;7(3):139-41.
43. Al-Kubaisy WA. Epidemiologic and genotypic distribution of hepatitis C in Iraqi pregnant women [PhD thesis]. Baghdad, Al Nahrain University. 1998.
44. Afzali H, Taghavi-Ardakani A, Vali GR. Seroepidemiology of hepatitis B and C in blood donors in Kashan, 1996-2001 [In persian]. FEYZ, Journal of Kashan University of Medical Sciences. 2002;23:43-51. (Abstract)
45. Khokhar N, Gill ML, Malik GJ. General seroprevalence of hepatitis C and hepatitis B virus infections in population. J Coll Physicians Surg Pak 2004;14:534-6.
46. Aghajanipoor K, Zandieh T. Seroepidemiological investigation of Hepatitis B, C and HIV virus in safe blood donors of Babol Blood Transfusion Center [In persian]. The Scientific Journal of Iranian Blood Transfusion Organization. 2005;2(7):339-41. (Abstract)
47. Aucella F, Vigilante M, Valente GL, Stallone C. Systematic monitor disinfection is effective in limiting HCV spread in hemodialysis. Blood Purification 2000;18(2):110-4.
48. Alavian SM, Bagheri-Lankarani K, Mahdavi-Mazdeh M, Nourozi S. Hepatitis B and C in dialysis units in Iran: Changing the epidemiology. Hemodial Int 2008;12(3):378-82.
49. Rahnavardi M, Hosseini Moghaddam SM, Alavian SM. Hepatitis C in hemodialysis patients: current global magnitude, natural history, diagnostic difficulties, and preventive measures. Am J Nephrol 2008;28(4):628-40.
50. Makris M, Preston FE, Triger DR, Underwood JC, Choo QL, Kuo G, et al. Hepatitis C antibody and chronic liver disease in haemophilia. Lancet 1990;335(8698):1117-9.
51. Brettler DB, Alter HL, Dienstag JL, Forsberg AD, Levine PH. Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients. Blood 1990;76:254-6.
52. Karimi M, Ghavanini AA. Seroprevalence of HBsAg, anti-HCV, and anti-HIV among haemophiliac patients in Shiraz, Iran. Haematologia 2001;31(3):251-5.
53. Alavian SM, Kafaei J, Yektaparast B, Hajarizadeh B, Kamali A, Sadri M, et al. The prevalence of Hepatitis B and C among thalassemia major patients in Qazvin [in Persian]. Kowsar Medical Journal 2002;4(7):325-19.
54. Mirmomen S, Alavian SM, Hajarizadeh B, Kafaee J, Yektaparast B, Zahedi MJ, et al. Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infecions in patients with beta-thalassemia in Iran: a multicenter study. Arch Iran Med. 2006;9:319-23.
55. Alavian SM, Kafaee J, Yektaparast B, Hajarizadeh B, Doroudi T. The efficacy of blood donor screening in reducing the incidence of hepatitis C virus infection among thalassemic patients in Iran. Transfusion Today 2002;53:3-4.
56. Al-Kubaisy WA, Al-Naib KT, Habib M. Seroprevalence of hepatitis C virus specific antibodies among Iraqi children with thalassaemia. East Mediterr Health J 2006;12(1-2):204-10.
57. Al-Hawsawi ZM. Prevalence of HCV antibody. Annals of Saudi Medicine 2000;20:488-9.
58. Kebudi R, Ayan I, Yilmaz G, Akici F, Gorgun O, Badur S. Seroprevalence of hepatitis B, hepatitis C, and human immunodeficiency virus infections in children with cancer at diagnosis and following therapy in Turkey. Medical and Pediatric Oncology 2000;34(2): 102-5.
59. Zali MR, Aghazadeh R, Nouroozi A, Amirrasooli H. Anti-HCV antibody among Iranian IV drug users: Is it a serious problem? Arch Iranian Med 2001;4(3):115-9.
60. Alavian SM, Ardeshiri A, Hajarizadeh B. Seroprevalence of anti-HCV Ab among Iranian hemophilia patients. Transfusion Today 2001;49:4-5.
61. Akbari A, Imanieh MH, Karimi M, Tabataba'i HR. Hepatitis C virus antibody positive cases in multitransfused thalassemic patients in South of Iran. Hepatitis Monthly 2007;7(2):63-6.
62. Alavian SM, Einollahi B, Hajarizadeh B, Bakhtiari S, Nafar M, Ahrabi S. Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients. Nephrology (Carlton). 2003;8(5):256-60.
63. Wreghitt TG. Blood-borne virus infections in dialysis units--a review. Reviews in Medical Virology 1999;9(2):101-9.
64. Zeldis JB, Depner TA, Kuramoto IK, Gish RG, Holand PV. The prevalence of hepatitis C virus antibodies among hemodialysis patients. Ann Intern Med 1990;112:958-60.
65. Santana GO, Cotrim HP, Mota E, Parana R, Santana NP, Lyra L. Antibodies to hepatitis C virus in patients undergoing hemodialysis in Salvador, BA, Brazil. Arq Gastroenterol 2001;38(1):24-31.
66. Hruby Z, Sliwinski J, Molin I, Zalewska M, Knysz B, Czyz W, et al. High prevalence of antibodies to hepatitis C virus in three haemodialysis centres in southwestern Poland. Nephrol Dial Transplant 1993;8(8):740-3.
67. Sanchez JL, Sjogren MH, Callahan JD, Watts DM, Lucas C, Abdel-Hamid M, et al. Hepatitis C in Peru: risk factors for infection, potential iatrogenic transmission, and genotype distribution. Am J Tropical Med Hygiene 2000;63(5-6):242-8.
68. Medeiros MT, Lima JM, Lima JW, Campos Hde H, Medeiros MM, Coelho Filho JM. Prevalence and associated factors to hepatitis C in hemodialysis patients in Brazil. Rev Saude Publica 2004;38(2):187-93.
69. Yang CS, Chang HH, Chou CC, Peng SJ. Isolation effectively prevents the transmission of hepatitis C virus in the hemodialysis unit. Journal of the Formosan Medical Association (Taiwan yi zhi) 2003; 102(2):79-85.
70. Jadoul M, Poignet JL, Geddes C, Locatelli F, Medin C, Krajewska M, et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant 2004;19(4):904-9.
71. Gallego E, Lopez A, Perez J. Effect of isolation measures on the incidence and prevalence of hepatitis C virus infection in hemodialysis. Nephron Clin Pract 2006;104:C1-C6.
72. Carneiro MA, Teles SA, Dias MA, Ferreira RC, Naghettine AV, Silva SA, et al. Decline of hepatitis C infection in hemodialysis patients in Central Brazil: a ten years of surveillance. Memorias do Instituto Oswaldo Cruz 2005;100(4):345-9.
73. Baril G, Traver JA. Decrease in the hepatitis C virus (HCV) prevalence in hemodialysis patients in Spain: Effect of time, initiating HCV prevalence studies and adoption of isolation measures. Antivir Res 2003;60:129-34.
74. Shamshirsaz AA, Kamgar M, Bekheirnia MR, Ayazi F, Hashemi SR, Bouzari N, et al. The role of hemodialysis machines dedication in reducing Hepatitis C transmission in the dialysis setting in Iran: a multicenter prospective interventional study. BMC Nephrol 2004;5(1):13.
75. Saxena Ak, Panhotra BR, Sundaram DS. Impact of dedicated space, dialysis equipment, and nursing staff on the transmission of hepatitis C virus in a hemodialysis unite of the Middle East. Am J Infect Control 2003;31:26-33.
76. Valtuille R, Moretto H, Lef L, Rendo P, Fernandez JL. Decline of high hepatitis C virus prevalence in a hemodialysis unit with no isolation measures during a 6-year follow-up. Clin Nephrol 2002;57(5):371-5.
77. Salama G, Rostaing L, Sandres K, Izopet J. Hepatitis C virus infection in French hemodialysis units: a multicenter study. J Med Virol 2000;61(1):44-51.
78. Sypsa V, Psichogiou M, Katsoulidou A, Skoutelis G, Moutafis S, Hadjiconstantinou V, et al. Incidence and patterns of hepatitis C virus seroconversion in a cohort of hemodialysis patients. Am J Kidney Dis 2005;45(2):334-43.
79. Covic A, Iancu L, Apetrei C, Scripcaru D, Volovat C, Mititiuc I, et al. Hepatitis virus infection in haemodialysis patients from Moldavia. Nephrol Dial Transplant 1999;14(1):40-5.
80. Schneeberger PM, Keur I, van Loon AM, Mortier D, de Coul KO, van Haperen AV, et al. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. J Infect Dis 2000;182(5):1291-9.
81. Sivapalasingam S, Malak SF, Sullivan JF, Lorch J, Sepkowitz KA. High prevalence of hepatitis C infection among patients receiving hemodialysis at an urban dialysis center. Infect Control Hosp Epidemiol 2002;23(6):319-24.
82. El-Amin HH, Osman EM, Mekki MO, Abderlraheem MB, Ismail MO, Yousif ME, et al. Hepatitis C virus infection in hemodialysis patients in Sudan: Two centers report. Saudi J Kidney Dis Transplant 2007;18:101-6.
83. Amiri ZM, Shakib AJ, Toorchi M. Seroprevalence of hepatitis C and risk factors in haemodialysis patients in Guilan, Iran. East Mediterr Health J 2005;11:372-6.
84. Al-Shohaib SS, Abd-Elaal MA, Zawawi TH, Abbas FM, Shaheen FA, Amoah E. The prevalence of hepatitis C virus antibodies among hemodialysis patients in Jeddah area, Saudi Arabia. Saudi Medical Journal 2003;2:S125.
85. Ben Othman S, Bouzgarrou N, Achour A, Bourlet T, Pozzetto B, Trabelsi A. High prevalence and incidence of hepatitis C virus infections among dialysis patients in the East-Centre of Tunisia. Pathologie Biologie 2004;52(6):323-7.
86. Shaheen FA, Huraib SO, Al-Rashed R. Prevalence of hepatitis C antibodies among hemodialysis patients in Jeddah area, Saudi Arabia. Saudi Medical Journal 2003;2:S125-S6.
87. Othman SB, Trabelsi A, Monnet A, Bouzgarrou N, Grattard F, Beyou A, et al. Evaluation of a prototype HCV NS5b assay for typing strains of hepatitis C virus isolated from Tunisian haemodialysis patients. Journal of Virological Methods 2004;119(2):177-81.
88. Lopez-Alcorocho JM, Barril G, Ortiz-Movilla N, Traver JA, Bartolome J, Sanz P, et al. Prevalence of hepatitis B, hepatitis C, GB virus C/ hepatitis G and TT viruses in predialysis and hemodialysis patients. J Med Virol 2001;63(2):103-7.
89. Santos MA, Souto FJ. Infection by the hepatitis C virus in chronic renal failure patients undergoing hemodialysis in Mato Grosso state, central Brazil: a cohort study. BMC Public Health 2007;7:32.
90. Hardy NM, Sandroni S, Danielson S, Wilson WJ. Antibody to hepatitis C virus increases with time on hemodialysis. Clin Nephrol 1992;38:44-8.
91. Yamaguchi K, Nishimura Y, Fukuoka N, Machida J, Ueda S, Kusumoto Y, et al. Hepatitis C virus antibodies in haemodialysis patients (2). Lancet 1990;335:1409-10.
92. Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Folsch UR, Schmidt WE. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut 2002;51(3):429-33.
93. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Miller LG, Daar ES, Gjertson DW, et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 2007;18(5):1584-93.
94. Albuquerque AC, Coelho MR, Lopes EP, Lemos MF, Moreira RC. Prevalence and risk factors of hepatitis C virus infection in hemodialysis patients from one center in Recife, Brazil. Memorias do Instituto Oswaldo Cruz 2005;100(5):467-70.
95. Carneiro MA, Martins RM, Teles SA, Silva SA, Lopes CL, Cardoso DD, et al. Hepatitis C prevalence and risk factors in hemodialysis patients in Central Brazil: a survey by polymerase chain reaction and serological methods. Memorias do Instituto Oswaldo Cruz 2001;96(6):765-9.
96. Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004;65(6):2335-42.
97. Ahmetagic S, Hantalasevic L, Tihic N, Jusufovic E, Stojic V. Hepatitis C virus infection in hemodialysis patients in General Hospital Gracanica. Medicinski Archiv 2006;60(5):298-300.
98. Ansar MM, Kooloobandi A. Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in north Iran-Rasht. J Viral Hepat 2002;9:390-2.
99. Bdour S. Hepatitis C virus infection in Jordanian haemodialysis units: serological diagnosis and genotyping. J Med Microbiol 2002;51(8):700-4.
100. Hussein MM, Mooij JM, Hegazy MS, Bamaga MS. The impact of polymerase chain reaction assays for the detection of hepatitis C virus infection in a hemodialysis unit. Saudi J Kidney Dis Transpl 2007;18(1):107-13.
101. Almroth G, Ekermo B, Mansson AS, Svensson G, Widell A. Detection and prevention of hepatitis C in dialysis patients and renal transplant recipients. A long-term follow up (1989-January 1997). J Intern Med 2002; 251(2):119-28.
102. Izopet J, Sandres-Saune K, Kamar N, Salama G, Dubois M, Pasquier C, et al. Incidence of HCV infection in French hemodialysis units: a prospective study. J Med Virol 2005;77(1):70-6.
103. Hmaied F, Ben Mamou M, Saune-Sandres K, Rostaing L, Slim A, Arrouji Z, et al. Hepatitis C virus infection among dialysis patients in Tunisia: incidence and molecular evidence for nosocomial transmission. J Med Virol 2006;78(2):185-91.
104. Sullivan DG, Kim SS, Wilson JJ, Stehman-Breen C, Gretch DR. Investigating hepatitis C virus heterogeneity in a high prevalence setting using heteroduplex tracking analysis. J Virol Methods 2001;96(1):5-16.
105. Iwasaki Y, Esumi M, Hosokawa N, Yanai M, Kawano K. Occasional infection of hepatitis C virus occurring in haemodialysis units identified by serial monitoring of the virus infection. J Hosp Infect 2000;45(1):54-61.
106. Kondili LA, Genovese D, Argentini C, Chionne P, Toscani P, Fabro R, et al. Nosocomial transmission in simultaneous outbreaks of hepatitis C and B virus infections in a hemodialysis center. Eur J Clin Microbiol Infect Dis 2006;25(8):527-31.
107. Delarocque-Astagneau E, Baffoy N, Thiers V, Simon N, de Valk H, Laperche S, et al. Outbreak of hepatitis C virus infection in a hemodialysis unit: potential transmission by the hemodialysis machine? Infect Control Hosp Epidemiol 2002;23(6):328-34.
108. Savey A, Simon F, Izopet J, Lepoutre A, Fabry J, Desenclos JC. A large nosocomial outbreak of hepatitis C virus infections at a hemodialysis center. Infect Control Hosp Epidemiol 2005;26(9):752-60.
109. Alfurayh O, Sabeel A, Al Ahdal MN, Almeshari K, Kessie G, Hamid M, et al. Hand contamination with hepatitis C virus in staff looking after hepatitis C-positive hemodialysis patients. Am J Nephrol 2000;20(2):103-6.
110. Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM, et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy 2007; 18(5):359-63.
111. Zali MR, Aghazadeh R, Nowroozi A. Anti-HCV antibody among Iranian IV drug users: is it a serious problem? Arch Iran Med 2001;4(3):115-9.
112. Alizadeh AHM, Alavian SM, Jafari K, Yazdi N. Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan - Iran. World J Gastroenterol 2005;11(26):4085-9.
113. Taylor A, Goldberg D, Frischer M, Emslie J, Green S, McKeganey N. Transmission of HIV in prison. Evidence of risk. Br Med J 1993;307(6904):623.
114. Muller R, Stark A, Guggenmoos-Holzmann I, Wirth D, Bienzle U. Imprisonment: a risk factor for HIV infection counteracting education and prevention programmes for intravenous drug users. AIDS. 1995;9:183-90.
115. Carvell ALM, Hart GJ. Risk behaviors for HIV infection among drug users in prison. Br Med J 1990;300:1383-85.
116. Covell RG, Frischer M, Taylor A. Prison experience of injecting drug users in Glasgow. Drug Alcohol Depend 1993;32:9-14.
117. Stark K, Muller R, Bienzle U, Guggenmoos-Holzmann I. Methadone maintenance treatment and HIV risk-taking behavior among injecting drug users in Berlin. J Epidemiol Community Health 1996;50(5):534-7.
118. Crofts N, Nigro L, Oman K, Stevenson E, Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction. 1997;92(8):999-1005.
119. Samuel MC, Doherty PM, Bulterys M, Jenison SA. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiol Infect 2001;127(3):475-84.
120. Hellard ME, Hocking JS, Crofts N. The prevalence and the risk behaviors associated with the transmission of hepatitis C virus in Australian correctional facilities. Epidemiol Infect 2004;132(3):409-15.
121. Hagan H, Des Jarlais DC. HIV and HCV infection among injecting drug users. Mt Sinai J Med 2000;67(5-6): 423-8.
122. Hagan H, Thiede H, Des Jarlais DC. HIV/hepatitis C virus coinfection in drug users: Risk behaviors and prevention. AIDS. 2005;19(Suppl.3): S199-S207.
123. Rezza G, Sagliocca L, Zaccarelli M, Nespoli M, Siconolfi M, Baldassarre C. Incidence rate and risk factors for HCV seroconversion among injecting drug users in an area with low HIV seroprevalence. Scand J Infect Dis 1996;28(1):27-9.
124. Thiede H, Hagan H, Murrill CS. Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health 2000;77(3):331-45.
125. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001;91(1):42-6.
126. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 2002;186(11):1558-64.
127. Judd A, Hickman M, Jones S, McDonald T, Parry JV, Stimson GV, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. Br Med J 2005;330(7481):24-5.
128. Judd A, Hutchinson S, Wadd S, Hickman M, Taylor A, Jones S, et al. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis. J Viral Hepat 2005;12(6):655-62.
129. Maher L, Li J, Jalaludin B, Chant KG, Kaldor JM. High hepatitis C incidence in new injecting drug users: a policy failure? Aust N Z J Public Health 2007;31(1):30-5.
130. Hagan H, Des Jarlais DC, Stern R, Lelutiu-Weinberger C, Scheinmann R, Strauss S, et al. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy 2007;18(5):341-51.
131. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008;48(1):148-62.
132. Alavian SM. Control of hepatitis C in Iran: vision and missions. Hepatitis Monthly 2007;7(2):57-558.